YB-1 Induces EGFR Expression in Basal-like Breast Cancer
Author Information
Author(s): Stratford Anna L, Habibi Golareh, Astanehe Arezoo, Jiang Helen, Hu Kaiji, Park Eugene, Shadeo Ashleen, Buys Timon PH, Lam Wan, Pugh Trevor, Marra Marco, Nielsen Torsten O, Klinge Uwe, Mertens Peter R, Aparicio Samuel, Dunn Sandra E
Primary Institution: University of British Columbia
Hypothesis
Does Y-box binding protein-1 (YB-1) regulate the expression of epidermal growth factor receptor (EGFR) in basal-like breast cancer (BLBC)?
Conclusion
Inhibition of EGFR in combination with suppression of YB-1 presents a potential opportunity for therapy in BLBC.
Supporting Evidence
- YB-1 is expressed in 73% of cases of basal-like breast cancer.
- EGFR is expressed in 57.1% of cases of basal-like breast cancer.
- YB-1 promotes EGFR reporter activity.
- Inhibiting EGFR with Iressa suppressed the growth of SUM149 cells by ~40%.
- YB-1 binds specifically to the EGFR promoter at two different YB-1-responsive elements.
Takeaway
Scientists found that a protein called YB-1 helps another protein, EGFR, grow in a type of aggressive breast cancer, and blocking both could help treat it.
Methodology
The study used immunostaining, comparative genomic hybridization, luciferase reporter assays, and cell growth measurements to evaluate the role of YB-1 in regulating EGFR.
Limitations
The study primarily focused on a limited number of breast cancer cell lines and may not represent all BLBC cases.
Participant Demographics
The study involved breast cancer tissue samples from women diagnosed with basal-like breast cancer.
Statistical Information
P-Value
3.899 × 10-4
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website